QUO VADIS BIOTECH

Biotechnology Today!

Biotechnology Tomorrow?

Invitation to Biotech Symposium | November 23rd 2010 | Sheraton Frankfurt Airport Hotel | Frankfurt/Main | Germany |
M+W Process Industries is pleased to invite you to attend the free of charge* symposium „Biotechnology Today ! - Biotechnology Tomorrow?“.

Ladies and gentlemen,

Let us invite you to the free of charge symposium Biotechnology Today ! - Biotechnology Tomorrow? at the Frankfurt Sheraton Airport Hotel, Germany, on November 23rd 2010. International speakers will outline latest trends and developments in the field of pharmaceutical biotechnology and facilities.

We would be very happy to welcome you to this event.

For more information or for registration please visit our webpage www.pi.mwgroup.net (events).

Please register until November 5th 2010.

We are looking forward to seeing you in Frankfurt.

Best regards

Frank Wilde
Head of Business Unit Bioprocess Facilities
M+W Process Industries GmbH, Germany

Armin Olbrich
Head of Business Unit Bioprocess Facilities

Hans-Jürgen Budde
Head of Business Development and Marketing

Morning Session

08:30 h - 09:10 h  Registration

09:15 h - 09:30 h  Welcome & introduction
Dr. Ulrich Behrendt
Chairman of the Association of German Biotechnology Companies (VBU – Dechema e. V.), former Vice President Fermentation Pharmaceutical Biotech Production of Roche Diagnostics GmbH, Germany

09:30 h - 10:10 h  Personalised Healthcare – Fitting the Treatment to the Patient
Dr. Horst Kramer, Project Leader ‘Roche Personalised Healthcare’ Communications, F. Hoffmann-La Roche Ltd, Switzerland

10:30 h - 10:50 h  Flexible Manufacturing for a Diverse Biologics Portfolio
Phillip L. Gomez, PhD, Director, PRTM Management Consultants, USA

10:50 h - 11:10 h  Morning Coffee

11:10 h - 11:50 h  Single-use Process Components - Opportunities and Constraints in an Evolving Business Environment
Dr. Peter Krämer, Director Process Development Engineering, Sanofi-Aventis Deutschland GmbH, Germany

11:50 h - 12:30 h  Flexible Facility Design for the Future: Dream or Reality?
Frank Wilde, Head of Business Unit Bioprocess Facilities, M+W Process Industries GmbH, Germany
Afternoon Session

Date/Location
Tuesday, November 23rd, 2010, 09:00 h - 17:00 h
Sheraton Hotel & Towers, Airport Frankfurt/Main, Germany

Language
English

Organizer
M+W Process Industries GmbH, Business Unit Bioprocess Facilities
Lotterbergstrasse 30, 70499 Stuttgart, Germany

Registration
www.pi.mwgroup.net (events)
Contact person: Ilga Palfner
phone: +49 71188 04 1822
fax: +49 711 88 04 1887
email: info.pi@mwgroup.net

Target Group
Biotechnology Companies | Pharmaceutical Companies

Who should attend?
CEOs | Heads of Production | Quality Assurance | Engineering | R&D |
Technical and Strategic Decision Makers | Project Leaders |

Accommodation
Travel and accommodation expenses not included. Rooms available at a special rate at the Sheraton Hotel, keyword „M+W Process Industries GmbH“. Please, make your reservation under phone +49 69 6977 1203 to 1206, fax +49 69 6977 2351 or e-mail reservationsfrankfurt@sheraton.com.

12:30 h - 13:30 h
Lunch

13:30 h - 14:10 h
Cell Culture-based Protein Production: From Titer Race to Fineness
Prof. Dr. Roland Wagner, Senior Vice President Development, Rentschler Biotechnologie GmbH, Germany

14:10 h - 14:50 h
Current and Future Developments in Downstream Processing, Technical and Economical Discussion of Biopharma Manufacturing Aspects
Dr. Günther Jagschies, Senior Director, Strategic Customer Relations, BioTechnologies R&D, GE Healthcare Life Sciences, Sweden

14:50 h - 15:10 h
Afternoon Tea

15:10 h - 15:50 h
Regulatory Issues for Usage of Disposable Systems in the Pharmaceutical Industry
Dr. Daniel Müller, GMP Inspector, Regional Council of Tuebingen Leitstelle Arzneimittelüberwachung Baden-Württemberg, Germany

15:50 h - 16:30 h
Biopharmaceuticals in Developing Companies
Scott M. Wheelwright, PhD, Strategic Manufacturing Worldwide, Inc., USA

16:30 h - 17:00 h
Final Questions and Wrap-up

17:00 h
End
Dr. Ulrich Behrendt, Chairman, Association of German Biotechnology Companies (VBU – Dechema e.V.) and former Vice President, Fermentation Pharmaceutical Biotech Production of Roche Diagnostics GmbH, Germany.

Since 2005: Chairman of the Association of German Biotechnology Companies (VBU – Dechema e.V.).

Roche Diagnostics GmbH, Penzberg: Vice President of Fermentation Pharmaceutical Biotech Production & Development (Microbial and Animal Cell Fermentation for Diagnostic & Therapeutic Proteins).

Boehringer Mannheim GmbH, Penzberg (since 1999 Roche Diagnostics GmbH): Director Development & Production Animal Biotechnology (Diagnostic & Therapeutic Proteins).

Boehringer Mannheim GmbH, Penzberg: Scientific Director Research and Development Animal Cell Biotechnology (Diagnostic & Therapeutic Proteins).

Dr. Philip L. Gomez, PhD, MBA, PRTM Management Consultants, Director, USA.

Dr. Phil Gomez has more than 15 years of experience bringing drugs and biologics to market in both the industry and government sectors. He joined PRTM from the Vaccine Research Center at NIAID/NIH.

Dr. Gomez earned the NIH Director’s Award in 2007 for the establishment of the Vaccine Pilot Plant and rapid production of a pandemic influenza vaccine. Prior to NIH, Dr. Gomez spent more than nine years in the pharmaceutical industry at Abbott Laboratories, Sanofi Pasteur, and Baxter Healthcare leading process/product development organizations and project teams for multiple biologic products. At PRTM, Dr. Gomez’s practice has focused on biologics development and manufacturing strategies. Dr. Gomez holds a Bachelor of Arts from Dartmouth College, a Master of Science in Chemical Engineering from Lehigh University, and a Master of Business Administration from the Smith School of Business at the University of Maryland.

Dr. Günther Jagschies, Senior Director, Strategic Customer Relations, BioTechnologies R&D, GE Healthcare Life Sciences, Sweden.

Senior Director, BioTechnologies R&D, GE Healthcare Life Sciences, Sweden, has been with GE Healthcare Life Sciences (former Amersham) for 25 years and has held senior management positions in sales, marketing, and R&D within the bioprocess division of the company. His current role is Senior Director Strategic Customer Relations (R&D and BioTechnologies business) working globally with industrial collaborations and as business advisor for the life sciences R&D and business team. He is based in Uppsala, Sweden.

Dr. Horst Kramer, Project Leader ‘Roche Personalised Healthcare’ Communications, F. Hoffmann-La Roche Ltd., Switzerland.

Within the Roche Group Communications department Dr. Horst Kramer is responsible for the global communication activities on ‘Roche Personalised Healthcare’. Based at the global headquarters in Basel, Switzerland, he has been driving communications activities within Roche Pharma and Diagnostics divisions and represented the Roche Group as corporate spokes-person since 1993. The main focus always was to educate the broad public on latest advances in medical care (e.g. virology, oncology) and progress in diagnostic testing technologies. Dr. Kramer graduated at the Free University Berlin, Germany, with a degree in veterinary medicine.

Dr. Peter Krämer, Director Process Development Engineering, Sanofi-Aventis Deutschland GmbH, Germany.

Peter Krämer is global head engineering in process development, he acts also as an engineering interface for major external (biotech) collaborations in Sanofi Aventis. He is based in Frankfurt and Paris. Prior to the global engagement, he was engineering director biotech production at Frankfurt during the phase of Aventis’ implementation of large scale recombinant (insulin) processes. He was technical site manager at a french (biotech) manufacturing site of Roussel UCLAF, french subsidiary of HOECHST AG. He started his career at HOECHST AG in 1990 as technical plant manager and member of a task force on economic evaluation of the companies’ pharmaceutical manufacturing network. He started his professional career with applied research and science management at DEHEMA, Frankfurt in 1993. He graduated in process engineering at the University of Stuttgart, he holds a PhD in biochemical engineering.

Dr. Daniel Müller, GMP Inspector, Regional Council of Tuebingen, Germany.

Daniel Mueller studied Pharmacy at the University of Wuerzburg, Germany, followed by doctorate. He started working in the pharmaceutical industry in 1998. Among other positions he served as a Qualified Person with responsibility for production, quality control and market release of large volume parenterals. In 2001 he joined a German Inspectorate at Tuebingen, Baden-Wuerttemberg. Since that time he has been working as a GMP-Inspector with focus on biotechnological active pharmaceutical ingredients and sterile drug products. He is a member of the German Expert Group No. 4 "Biotechnology & Tissue" and he has a further qualification as ‘Fachapotheke für Pharmazeutische Analytik’ and ‘Fachapotheke für Öffentliches Gesundheitswesen’.

Prof. Dr. Roland Wagner, Senior Vice President Development, Rentschler Biotechnologie GmbH, Germany.

Roland Wagner is Senior Vice President of the Development Division at Rentschler Biotechnologie GmbH in Laupheim, Germany, one of the considerable contract manufacturing organizations for cell culture processes worldwide. He has a degree in Biology from the Technical University of Braunschweig from where he also received his Ph.D. and postdoctoral lecture qualification (“Habilitation”) in Biotechnology. After his post doctoral studies, he held position of the Director of the Cell Culture Technology Dept. at the German Research Centre for Biotechnology (MBB) in Braunschweig. Subsequently, Roland Wagner worked as Director of the R&D Bioprocess Science Dept. at Miltenyi Biotec GmbH in Germany, a leading company in cell separation, stem cell research and cell therapeutic products. Roland is a.o. Professor for Biotechnology in Braunschweig. He has an extensive list of publications and holds several patents.

Scott M. Wheelwright, PhD, Strategic Manufacturing Worldwide, Inc., USA.

Scott M. Wheelwright, PhD, is founder and principal of the firm Strategic Manufacturing Worldwide, Inc., a consulting firm focused on manufacturing compliance and outsourcing with offices in the US and China. Dr. Wheelwright has over twenty five years experience in bringing novel products to market with work experience that encompasses both large and small pharmaceutical firms and biotech companies. Dr. Wheelwright received his Ph.D. in chemical engineering from the University of California at Berkeley and performed post-doctoral studies at the Max Planck Institute for Biophysics in Frankfurt, Germany. He is the author of a book on protein purification and has published numerous articles on manufacturing and process development.

Frank Wilde, Head of the Business Unit Bioprocess Facilities at M+W Process Industries GmbH, Stuttgart, Germany.

He has participated as process engineering manager and project manager in several large scale biotech projects for production-, pilot- and R&D-facilities. Prior to his position at M+W Process Industries GmbH, he worked as a project manager at Bioengineering AG in Switzerland, a leading equipment supplier for the biopharmaceutical industry. Mr. Wilde graduated at the University of Applied Sciences at Mannheim, Germany, with a chemical engineering/biotechnology degree.